Fig. 4: Treatment and pre-exposure prophylaxis with EIDD-2801 potently inhibit SARS-CoV-2 infection in vivo.
From: SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
a, SARS-CoV-2 titres in the human lung tissue of LoM administered EIDD-2801 (n = 8) or vehicle control (n = 8) 24 h after exposure to virus. b, SARS-CoV-2 titres in the human lung tissue of LoM administered EIDD-2801 (n = 8) or vehicle (n = 8) 48 h after exposure to virus. c, d, SARS-CoV-2 titres in the human lung tissue of LoM administered EIDD-2801 (n = 8 per experiment) or control vehicle (n = 8 per experiment) 12 h before exposure to virus in two independent experiments shown separately (c) and combined (d). e, Fold difference in SARS-CoV-2 titres in the human lung tissue of LoM administered EIDD-2801 12 h before exposure to virus relative to vehicle controls. f, g, H&E staining (f) and immunohistochemical staining (g) for virus nucleoprotein (nucleoprotein-positive cells, brown) of human lung tissue of LoM administered EIDD-2801 (n = 8) or control vehicle (n = 8) 12 h before exposure to virus. Scale bars, 100 μm. a–d, Titres were compared with a two-tailed Mann–Whitney U test. Horizontal and vertical lines represent the median and interquartile range, respectively. n, number of biologically independent lung tissues analysed.
